RecruitingPhase 2

Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers

United States100 participantsStarted 2025-09-09

Plain-language summary

The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are: Do Obicetrapib effect absorption of antioxidants in a person's blood or their eye tissue? Researchers will compare Obicetrapib to a placebo (a look-alike substance that contains no drug) to see if Obicetrapib helps improve a person's ability to absorb antioxidants. Participants will: Take Obicetrapib or a placebo every day for 4 months Visit the clinic once every 8 weeks for checkups and tests Have their blood taken and their eyes checked to measure antioxidant levels

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Visual acuity \> 20/60 in both eyes with or without corrective lenses Exclusion Criteria: * Type 2 diabetes * Active liver disease * Any clinically significant macular pathology

What they're measuring

Sum of Percent Change of Antioxidant Levels within HDL

Timeframe: 16 Weeks

Trial details

NCT IDNCT06982508

SponsorNewAmsterdam Pharma

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-09

View on ClinicalTrials.gov More Antioxidant Absorption trials